Trial results for rimegepant for the acute treatment of migraine in adults unsuitable for triptan use were posted on ClinicalTrials.gov on 2026-04-21. The study demonstrated that 55.9% of participants receiving rimegepant achieved pain relief at 2 hours post-dose, compared to 32.7% for placebo. Additionally, 22.7% of rimegepant recipients achieved pain freedom at 2 hours, versus 7.4% for placebo.
Background
Migraine is a debilitating neurological condition. This study specifically focused on adults with migraine who are unsuitable for triptan medications, a common class of acute migraine treatments. Reasons for triptan unsuitability included previous intolerance, lack of efficacy, or contraindications such as a history of clinically-relevant cardiovascular disease.
Trial design
This Phase 4, completed study (NCT05509400) enrolled 813 participants with Migraine. The trial evaluated the efficacy and tolerability of rimegepant compared to placebo for the acute treatment of migraine in adults who were unsuitable for triptan use.
Key results
The trial results showed significant differences between rimegepant and placebo across several key outcomes at 2 hours post-dose:
- For pain relief at 2 hours post-dose, 55.9% of participants in the rimegepant group achieved relief, compared to 32.7% in the placebo group. The crude risk estimation showed a difference of 23.2 percentage points (95% Confidence Interval: 15.3 to 31.1; p-value: 0.0001).
- For pain freedom at 2 hours post-dose, 22.7% of participants in the rimegepant group achieved freedom, compared to 7.4% in the placebo group. The crude risk estimation showed a difference of 15.3 percentage points (95% Confidence Interval: 9.6 to 21.1; p-value: 0.0001).
- The percentage of participants who used rescue medications within 24 hours post-dose was 18.0% for rimegepant versus 46.2% for placebo. The crude risk estimation showed a difference of -28.2 percentage points (95% Confidence Interval: -35.6 to -20.8; p-value: 0.0001).
- For return to normal function at 2 hours post-dose, 28.9% of participants in the rimegepant group achieved this, compared to 12.7% in the placebo group. The crude risk estimation showed a difference of 16.2 percentage points (95% Confidence Interval: 9.0 to 23.4; p-value: 0.0001).
- Sustained return to normal function from 2 to 24 hours post-dose was observed in 18.1% of rimegepant participants versus 6.8% of placebo participants. The crude risk estimation showed a difference of 11.4 percentage points (95% Confidence Interval: 5.5 to 17.2; p-value: 0.0002).
- Sustained return to normal function from 2 to 48 hours post-dose was observed in 15.9% of rimegepant participants versus 4.2% of placebo participants. The crude risk estimation showed a difference of 11.7 percentage points (95% Confidence Interval: 6.4 to 17.1; p-value: 0.0001).
What this means
The results of this Phase 4 trial indicate that rimegepant is effective for the acute treatment of migraine in adults who cannot use triptan medications. The significant improvements in pain relief, pain freedom, and return to normal function at 2 hours post-dose, along with reduced rescue medication use, suggest that rimegepant offers a valuable treatment option for this specific patient population. The sustained benefits observed for up to 48 hours further support its utility.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05509400, titled "Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use," were posted on 2026-04-21 on clinicaltrials.gov.